Cai Shengnan, Zhang Yue-Xiang, Han Ke, Ding Yi-Qian
Affiliated Maternity and Child Care Hospital of Nantong University, Nantong Zhongnan Century City Chongchuan District 12 Building 2 Unit 1105 Room, Nantong, Jiangsu, China.
Affiliated Drum Tower Hospital of Nanjing University Medicine School, Nanjing, China.
Arch Gynecol Obstet. 2017 Jul;296(1):93-98. doi: 10.1007/s00404-017-4386-9. Epub 2017 May 4.
The article is to study the expressions of COX-2, VEGF-C, and EGFR in endometrial carcinoma as well as its clinical significances.
Clinical data of 183 patients with endometrial carcinoma who received surgery as initial treatment in the Nanjing Drum Tower Hospital Affiliated to the Nanjing University Medical School and the Nantong Maternal and Child Health Hospital Affiliated to the Nantong University from January 2005 to December 2010 were retrospectively investigated; 152 out of the 183 patients were closely followed up. Expressions of COX-2, VEGF-C, and EGFR proteins in 152 endometrial carcinoma samples were detected by immunohistochemical S-P assay.
A 5-year survival rate of 152 patients was 81.56% (124/152). Positive COX-2 expression rate was 67.76% (103/152), and its positive expression was related to FIGO stage, differentiation degree, and myometrial invasion depth of patients (P < 0.05), but not to lymph node metastasis (P > 0.05). Positive expression rates of VEGF-C and EGFR were 64.47% (98/152) and 82.24% (125/152), respectively, and their positive expression was associated with FIGO stage, differentiation degree, myometrial invasion depth, and lymphatic metastasis (P < 0.05). Correlation analysis on the expression of COX-2 with VEGF-C and of EGFR found that COX-2 was positively correlated with both VEGF-C and EGFR (P < 0.05, r > 0). Patient prognosis was associated with the FIGO stage, differentiation degree, and myometrial invasion depth of tumors, as well as the presence or absence of lymph node metastasis (P < 0.05) while showing no significant association with the postoperative adjuvant therapy (P > 0.05).
COX-2, VEGF-C, and EGFR are of significance for determining the FIGO stage, differentiation degree, and myometrial invasion depth of endometrial carcinoma, of which VEGF-C and EGFR are important in determining whether tumors metastasize to lymph nodes. Combined detection of COX-2, EGFR, and VEGF-C can be used as the indices for early diagnosis, recurrence prediction, and outcome evaluation for patients with endometrial carcinoma.
研究环氧化酶-2（COX-2）、血管内皮生长因子-C（VEGF-C）和表皮生长因子受体（EGFR）在子宫内膜癌中的表达及其临床意义。
回顾性分析2005年1月至2010年12月在南京大学医学院附属南京鼓楼医院及南通大学附属南通妇幼保健院接受手术治疗的183例子宫内膜癌患者的临床资料；其中152例患者进行了密切随访。采用免疫组织化学S-P法检测152例子宫内膜癌组织中COX-2、VEGF-C和EGFR蛋白的表达。
152例患者的5年生存率为81.56%（124/152）。COX-2阳性表达率为67.76%（103/152），其阳性表达与患者的国际妇产科联盟（FIGO）分期、分化程度及肌层浸润深度有关（P<0.05），与淋巴结转移无关（P>0.05）。VEGF-C和EGFR阳性表达率分别为64.47%（98/152）和82.24%（125/152），其阳性表达与FIGO分期分化程度、肌层浸润深度及淋巴结转移有关（P<0.05）。COX-2与VEGF-C及EGFR表达的相关性分析发现，COX-2与VEGF-C和EGFR均呈正相关（P<0.05，r>0）。患者预后与肿瘤的FIGO分期、分化程度、肌层浸润深度及有无淋巴结转移有关（P<0.05），与术后辅助治疗无关（P>0.05）。
COX-2、VEGF-C和EGFR对判断子宫内膜癌的FIGO分期、分化程度及肌层浸润深度有重要意义，其中VEGF-C和EGFR对判断肿瘤是否发生淋巴结转移具有重要作用。联合检测COX-2、EGFR和VEGF-C可作为子宫内膜癌患者早期诊断、复发预测及疗效评估的指标。
